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Abstract
Background: Genome-wide profiling of rare tumors is crucial for improvement of diagnosis, treatment, and,
consequently, achieving better outcomes. Desmoplastic small round cell tumor (DSRCT) is a rare type of sarcoma
arising from mesenchymal cells of abdominal peritoneum that usually develops in male adolescents and young
adults. A specific translocation, t(11;22)(p13;q12), resulting in EWS and WT1 gene fusion is the only recurrent
molecular hallmark and no other genetic factor has been associated to this aggressive tumor. Here, we present a
comprehensive genomic profiling of one DSRCT affecting a 26-year-old male, who achieved an excellent outcome.
Methods: We investigated somatic and germline variants through whole-exome sequencing using a family based
approach and, by array CGH, we explored the occurrence of genomic imbalances. Additionally, we performed
mate-paired whole-genome sequencing for defining the specific breakpoint of the EWS-WT1 translocation,
allowing us to develop a personalized tumor marker for monitoring the patient by liquid biopsy.
Results: We identified genetic variants leading to protein alterations including 12 somatic and 14 germline events
(11 germline compound heterozygous mutations and 3 rare homozygous polymorphisms) affecting genes
predominantly involved in mesenchymal cell differentiation pathways. Regarding copy number alterations (CNA)
few events were detected, mainly restricted to gains in chromosomes 5 and 18 and losses at 11p, 13q, and 22q. The
deletions at 11p and 22q indicated the presence of the classic translocation, t(11;22)(p13;q12). In addition, the mapping
of the specific genomic breakpoint of the EWS-WT1 gene fusion allowed the design of a personalized biomarker
for assessing circulating tumor DNA (ctDNA) in plasma during patient follow-up. This biomarker has been used
in four post-treatment blood samples, 3 years after surgery, and no trace of EWS-WT1 gene fusion was detected, in
accordance with imaging tests showing no evidence of disease and with the good general health status of the patient.
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Conclusions: Overall, our findings revealed genes with potential to be associated with risk assessment and tumorigenesis
of this rare type of sarcoma. Additionally, we established a liquid biopsy approach for monitoring patient follow-up based
on genomic information that can be similarly adopted for patients diagnosed with a rare tumor.
Keywords: Desmoplastic small round cell tumor, Genomic profiling, Whole-exome sequencing, EWS-WT1 gene fusion,
Personalized biomarker, Liquid biopsy
Background
Comprehensive molecular profiling is an especially im-
portant tool to gain insights on the biological pathways
involved in tumor onset and to improve the manage-
ment and treatment of rare tumors. Desmoplastic small
round cell tumor (DSRCT) is a very rare type of sarcoma,
with an age-adjusted incidence rate of 0.3 cases/million
[1], which typically arises from the abdominal or pelvic
peritoneum and occurs mainly in male adolescents and
young adults (peak incidence at 20–24 years of age) [1].
Current therapeutic approaches involve the use of multi-
modal therapeutic regimen, including aggressive poly-
chemotherapy, debulking surgery, and whole abdominal
radiation [2].
A specific translocation, t(11;22)(p13;q12), is detected
in DSRCT cases, juxtaposing the Ewing’s sarcoma gene
(EWSR1) to the Wilm’s tumor gene (WT1). The chimeric
transcript containing the 5′ region of the EWSR1, which
includes the N-terminal transactivation domain of EWS,
and the 3′ sequence of WT1 containing 2–4 zinc finger
domains have been shown to upregulate EGR-1 [3] and
induce the expression of PDGFA [4] and IGF1R [5].
Apart from this translocation, no other recurrent gen-
omic alteration has been reported in DSRCT cases. Silva et
al. [6] detected a somatic amplification involving AURKB
and MCL1 genes in one patient, and La Starza et al. [7]
found specific genomic imbalances, including gain at
chromosome 3 reported in two cases and chromosome
5 polysomy in one case. In terms of point mutations,
the data is even scarcer. Variants of unknown clinical
significance were reported in ARID1A and RUNX1
genes in one patient [6], whereas in another study, no
mutations were detected in a panel of 29 genes evaluated
in a cohort of 24 DSRCT cases [8]. This limited genomic
information about DSRCT impairs new and more efficient
therapeutic opportunities for the young patients affected
with this rare tumor.
Here, aiming to contribute with the knowledge of the
genomic abnormalities that underlies DSRCT, we per-
formed a comprehensive genomic profiling using a
family based approach in one case of DSRCT diagnosed
in a young male patient with pelvic tumor, who pre-
sented excellent outcome sustained for above 3 years.
We identified somatic mutations in a genomic back-
ground of rare germline variants either homozygous or
as compound heterozygous inheritance, which can im-
prove the understanding of the genetic basis of this rare
tumor. We have also generated the profile of genomic
imbalances, which was confirmed by whole-exome se-
quencing. In addition, as we were able to define the
precise genomic breakpoints of the EWS-WT1 trans-
location by whole-genome and Sanger sequencing, we
managed to establish a personalized strategy for tracking
DNA tumor traces in plasma, allowing an accurate moni-
toring of tumor recurrence.
Overall, our analysis revealed potential genes and path-
ways associated with this rare sarcoma and demonstrated
the feasibility of using genomic profiling for the benefit of




Tumor tissues and blood samples were collected following
the technical and ethical procedures of A.C. Camargo
Tumor Bank, registered at National Council for Ethics in
Research by the number B001 [9]. Genomic DNA and
plasma DNA were extracted in DNA and RNA Bank [10]
using QIASymphony DNA Mini kit (QIAGEN, Hilden,
Germany) for tumor and leukocyte DNA and QIAamp
DNA blood Midi kit (QIAGEN, Hilden, Germany) for
plasma DNA, following standard procedures.
Target sequencing
Target sequencing was performed using the Ion Ampli-
Seq™ Comprehensive Cancer Panel, which comprises all
exons from 409 genes associated with different types of
tumors (AmpliSeq, Ion Torrent™). This panel, based on
multiplex PCR, was performed with as little as 40 ng of
DNA from the tumor sample. Library was prepared based
on Ion AmpliSeq™ Library Preparation protocol and se-
quenced at Ion Proton™ platform (Ion Torrent™), accord-
ing to the manufacturer’s instructions.
Whole-exome sequencing
Whole-exome sequencing of the tumor and leukocyte
DNA samples from the patient and his mother were per-
formed using the TargetSeq™ Exome Enrichment Kit (Life
Technologies), followed by paired-end sequencing (75 × 50)
in SOLiD 5500xl System (Life Technologies). Leukocyte
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DNA sample from his father was submitted for whole-
exome sequencing using Ion Xpress™ Plus Fragment Li-
brary kit and Ion TargetSeq™ Exome Enrichment Kit (Life
Technologies), followed by sequencing at Ion Proton™
platform (Ion Torrent™), according to the manufacturer’s
instructions. Single-end sequencing was performed on
an Ion PI™ Chip v2 with 200 pb sequencing kit (Ion
Torrent™).
Whole-genome sequencing
Whole-genome sequencing was performed by mate-paired
DNA libraries prepared using the 5500 SOLiD™ Mate-
Paired Library Construction Kit (Life Technologies), fol-
lowing the manufacturer’s instructions. Briefly, genomic
DNA from tumor and leukocyte of the patient was
sheared with a Covaris sonicator into approximately
2 Kb fragments, circularized with mate-paired adaptors,
nick-translated and digested, incorporated with sequencing
adaptors and individual barcodes (distinct barcodes were
used for the tumor and leukocyte DNA), and submitted to
emulsion PCR. Mate-paired sequencing (60 × 60) was per-
formed in a SOLiD 5500xl System (Life Technologies).
Sanger sequencing
For validation, primers were designed flanking the vari-
ants, in order to generate fragments of nearly 400 bp. PCR
reactions were performed using GoTaq® Green Master
Mix (Promega, Madison, WI, USA), using 15 ng of DNA,
with 300 nM of each primer, for a final reaction volume
of 20 μL. Approximately 200 ng of PCR-amplified frag-
ments were purified with ExoSAP-IT (USB Corporation,
Cleveland, OH, USA) and sequenced in both directions.
All alterations were evaluated in all four samples (mother,
father, and patient’s leukocyte and tumor). Products were
analyzed using an ABI 3130xl DNA sequencer (Applied
Biosystems, Foster City, CA, USA), and sequences were
aligned with the respective gene reference sequence using
CLC Genomics Workbench Software (QIAGEN, Hilden,
Germany).
Comparative genome hybridization based on microarrays
(array CGH)
Comparative genomic hybridization based on microar-
rays was performed in a commercial whole-genome 180 K
platform containing 180,000 oligonucleotide probes
(Agilent Technologies; design 22060), using DNA from
the tumor sample. Reference DNA was a commercially
available human pool of samples from multiple anonymous
healthy donors (Promega Corporation). Technical proce-
dures are described in Torrezan et al. [11]. Hybridization
and washing were performed as recommended by the
manufacturer. Scanned images were processed using Fea-
ture Extraction 10.7.3.1 software (Agilent Technologies),
and array CGH analysis was conducted with Nexus Copy
Number software 7.0 (Biodiscovery). We used the FASST2
segmentation algorithm, according to the following settings:
minimum of five consecutive probes (effective resolution of
~70 Kb for CNA calling), significance threshold set at 10−8,
and threshold log2 Cy3/Cy5 of 0.33 and −0.3 for gains
for loss, respectively, and 1.2 and −1.1 for high copy
number gains and homozygous losses, respectively. All
copy number alterations are reported in the Database
of Genomic Variants [12].
Bioinformatics analysis
Comprehensive cancer panel
Sequencing reads from Ion Proton™ were mapped to the
reference genome (GRCh37/hg19) with TMAP (torrent
mapper 4.2.18). Sequence variants (SNVs and indels) were
identified with Torrent Variant Caller 4.0-5, followed by
confirmation by GATK protocol vs3.2-2-gec30cee [13].
Variants were annotated using SnpEff version 3.5d (build
2014-03-05) [14].
Whole-exome sequencing
Sequencing reads from SOLiD 5500xl System were mapped
to the reference genome (GRCh37/hg19) with Lifescope
(LifeScope™ Genomic Analysis Software v2.5.1). Sequencing
reads from Ion Proton™ were mapped to the reference
genome (GRCh37/hg19) with TMAP (torrent mapper
4.2.18). Sequence variants (SNVs and indels) were iden-
tified following the GATK protocol vs3.2-2-gec30cee
[13] for SOLiD 5500XL System and with Torrent Vari-
ant Caller 4.0-5, followed by GATK protocol vs3.2-2-
gec30cee for Ion Proton reads. Variants were annotated
using SnpEff version 3.5d (build 2014-03-05) [14] and an
in-house developed script. Identified variants were com-
pared to dbNSFP version 2.4 [15, 16]; COSMIC v69 [17];
1000 Genomes [18]; NHLBI GO Exome Sequencing Pro-
ject version ESP6500SI-V2 [19]; HapMap [20]; and dbSNP
version 138 [21, 22] for further annotation. Somatic vari-
ants were defined for regions with a minimum coverage of
10× for both tumor and leukocyte sample from the patient
and minimum variant frequency of 20% in the tumor only.
De novo variants were defined with a minimum coverage
of 10× for leukocyte samples of the patient and his parents
and with a minimum variant frequency of 30%. To identify
rare polymorphisms inherited in homozygosity, we se-
lected variants with a minimum coverage of 10× for
leukocyte samples of the patient and his parents, detected
in heterozygosis in both parents and homozygosis in the
patient presenting a minor allele frequency ≤10% in the
public databases (1000 Genome [18], NHLBI GO Exome
Sequencing Project [19], and HapMap [20]). To identify
germline compound heterozygosis cases, we identified
genes with two distinct heterozygous mutations in the pa-
tient, where each variant was exclusively present in one of
his parents in heterozygosity and detected in regions with
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a minimum coverage of 10× for all leukocyte samples. We
discarded variants that are detected with a minor allele
frequency above 10% in the 1000 Genome Project [18].
Copy number alterations were detected using the bioinfor-
matics packages Excavator (version 2.2) [23] and cn.mops
(version 1.8.9) [24] by comparing exome data from the
tumor to leukocyte from the patient. For visualization,
we used circos 0.67-7 package [25].
Whole-genome sequencing
For detecting structural variations, mate-pair reads ob-
tained by SOLiD 5500xl System were analyzed by svdetect
(version r0.8b) [26].
Ingenuity Pathway Analysis
We applied the core analysis of Ingenuity Pathway Analysis
(IPA) system (QIAGEN, Germantown, MD, USA) to iden-
tify gene interaction networks.
Digital droplet PCR
Digital droplet PCR assays were carried out using the
QX200™ Droplet Digital™ (ddPCR™) System (Bio-Rad). A
primer-probe assay labeled with FAM was designed for
the amplification of wild-type WT1 gene and a primer-
probe assay labeled with HEX was designed for the
amplification of the gene fusion event (EWS-WT1). For
the amplification reaction, we used 1× ddPCR Super-
mix, 1× primer-probe assay (FAM), 1× primer-probe
assay (HEX), and 4 μl of DNA. Droplet generation, PCR
amplification, and droplet counting were performed fol-
lowing the manufacturer’s recommendations.
DNA samples from tumor tissue (60 ng–6 pg) and from
leukocytes (6 ng) were used as positive and negative con-
trols, respectively. We loaded 4 μl of 30 μl (1/8) of cfDNA
samples from the patient. We also used DNA and cell-free
DNA extracted from leukocytes and plasma, respectively,
from healthy donors as negative controls and performed
non-template control. All reactions were performed with
at least two replicates.
Results
In this study, we performed a comprehensive genomic
profiling of one case of desmoplastic small round cell
tumor (DSRCT) by a combination of targeted sequencing,
array CGH, whole genome, and whole exome applied in a
family based format. The patient studied here is a 26-year-
old male, who presented at A.C. Camargo Cancer Center
in November, 2011, with a large abdominal mass and a
small nodule on the pelvic region. Staging images showed
that the disease was limited to the abdominal cavity. He
underwent a CT-guided biopsy that revealed a desmo-
plastic small round cell tumor (DSRCT), showing posi-
tivity for EMA, desmin, and nuclear staining for WT1
(carboxy-terminus antibody). FISH analysis was positive
for EWS translocation.
The patient started systemic treatment with 4 cycles of
vincristine, cyclophosphamide, and doxorubicin (VAC)
and alternated with ifosfamide, carboplatin, and etopo-
side (ICE). After 4 cycles, the best response was stable
disease, with minor reduction in the tumor dimensions.
He underwent complete surgical cytoreduction, with
resection of the large mass and resection of peritoneal
implant on the pelvic region, and hyperthermic intra-
peritoneal chemotherapy (HIPEC), with cisplatin and
doxorubicin. The patient presented a complete recovery
from these procedures. After that, the patient received
four more cycles of chemotherapy and total abdominal
irradiation (total of 30 Gy). After a follow-up of 48 months
since surgery, the patient is asymptomatic, with no signs
of disease (Additional file 1: Figure S1).
The comprehensive genomic profiling was carried out
in multiple fronts. To identify actionable mutations, we
carried out targeted sequencing of the most important
actionable genes in the tumor sample. Further, to iden-
tify genes and mutations possibly involved with tumor
onset and predisposition, we performed whole exome se-
quencing, using the DSRCT tumor sample and blood
samples from the patient and his both parents (Additional
file 2: Table S1). Array CGH was performed in tumor
sample to identify structural rearrangements and copy
number imbalances. Whole-genome sequencing defined
one tumor marker used to precisely monitor patient after
treatment.
Producing a portrait of somatically acquired variants
To identify actionable mutations or pathways related to
DSRCT in this patient, we initially performed targeted se-
quencing using a cancer-oriented gene panel composed of
409 genes in the tumor sample (Comprehensive Cancer
Panel – Thermo Scientific). Since no actionable mutation
for targeted therapy was detected in the tumor, we in-
vestigated the complete landscape of somatic mutations
by whole-exome sequencing (WES) the tumor and the
patient’s leukocyte. The analysis of the tumor revealed
15 somatic acquired mutations, 12 of which were protein-
affecting variants (validated by capillary sequencing) in-
cluding one non-sense mutation in the ZNF808 gene, one
nucleotide change at the 3’ splice site of RIMS4, and 10
missense mutations considered disease associated by at
least one pathogenicity prediction program (Table 1).
Gene ontology enrichment analysis of the 12 genes
harboring protein-affecting somatic mutations revealed
several biological processes such as muscle tissue/organ
development (ZFPM2 and MEGF10), which is related
to the mesothelium origin of this tumor, cell adhesion
(DPP4, CDH9, CNTNAP4, MEGF10), response to mech-
anic stimulus (MEIS2, TRPA4), and response to abiotic
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stimulus (DPP4, MEIS2, TRPA1) (Additional file 3:
Table S2). Intriguingly, biological network analysis ob-
tained using Ingenuity Pathway Analysis (IPA) inter-
connected the 15 genes harboring somatic mutations in
a single network associated with cell death and survival,
cell damage or degeneration, and nervous system devel-
opment and function (Fig. 1a).
Searching for germline variants associated with DSRCT
In an attempt to identify de novo germline mutations and
inherited variants potentially associated with DSRCT, we
performed whole-exome sequencing of the leukocyte DNA
from the patient’s parents (Additional file 2: Table S1). For
selecting genetic variants, a minimum coverage of 10× in
all samples with at least 30% frequency of the variant allele
was considered. Based on these criteria, no de novo
variants were found.
Next, we explored the possibility of finding genetic
variants associated with DSRCT in an autosomal reces-
sive model of inheritance. First, we searched for poly-
morphisms (MAF ≤10%) occurring in homozygosity in
the patient that were inherited from both heterozygous
parents. Four polymorphisms inherited in homozygosis
were found in ADAMTS12, RASSF1,VEZT, and ISX genes
(population frequency ranging from 2.0 to 7.8%). All poly-
morphisms lead to missense alterations, two of them re-
ported as possibly disease associated by at least one
pathogenicity prediction program (Table 2). Interestingly,
biological network analysis showed an interconnection
between the four genes in a single network from IPA,
showing association with cell cycle and digestive system
development and function (Fig. 1b).
Next, to identify candidate genes affected by compound
heterozygosity, we looked for genes containing two dis-
tinct variants inherited independently from each parent.
We could confirm 11 genes affected by germline com-
pound heterozygous mutations, in which one variant allele
was inherited from the mother and the other variant allele
was inherited from the father (MAF ≤10%) (Table 3). We
speculate that these genes could be associated with risk
to DSRCT development in an autosomal recessive
model of inheritance.
Gene ontology analysis of these 11 genes showed en-
richment of biological processes related to muscle tissue
development (LAMB2, SYNE1, and TTN), morphogen-
esis (C2CD3 and TTN), and cell cycle (RSPH1, TTN, and
SPICE1) (Additional file 4: Table S4). Functional analysis
of IPA revealed that 9 of the 11 genes are interconnected
in a single network related to cancer, organismal injury
and abnormalities, and gastrointestinal disease.
Copy number alterations
Genomic copy number alterations (CNA) were investi-
gated in the DSRCT tumor sample using array CGH in
a 180-K platform. Few copy number alterations were de-
tected (Fig. 2a), including aneuploidies such as gain of chro-
mosomes 5 and 18, and 11p, 13q, and 22q deletions. Only
one small focal homozygous deletion was identified in a
segment of ~1.3 Mb at 9p22.2 (chr9:17,106,384-18,449,088;
hg19), encompassing the CNTLN and SH3GL2 genes.











dbSNP PolyPhen Sift Mutation taster
chr3:436494 CHL1 c.3033A>G, p.A111A Synonymous 35% (55×) 53× – – – –
chr6:134305546 TBPL1 c.315T>G, p.V105V Synonymous 23% (31×) 28× – – – –
chr12:34179763 ALG10 c.1335A>T, p.A445A Synonymous 43% (82×) 66× – – – –
chr1:45808899 TOE1 c.1058C>T, p.P353L Missense 20% (15×) 18× rs145913038 Benign Damaging Polymorphism
chr2:162875307 DPP4 c.1352C>T, p.P451L Missense 37% (41×) 46× – Deleterious Tolerated Disease causing
chr5:126753368 MEGF10 c.1169G>C, p.G390C Missense 22% (82×) 39× – Deleterious Damaging Disease causing
chr5:26915867 CDH9 c.394G>C, p.D132Y Missense 25% (71×) 75× – Deleterious – Disease causing
chr6:123319098 CLVS2 c.176G>A, p.R59Q Missense 40% (25×) 20× – Deleterious Damaging Disease causing
chr8:106813312 ZFPM2 c.1002T>A, p.S334R Missense 28% (36×) 44× – Deleterious Tolerated Disease causing
chr8:72983969 TRPA1 c.245T>C, p.I82T Missense 36% (45×) 35× – Deleterious Damaging Disease causing
chr15:37385900 MEIS2 c.521G>A, p.R86Q Missense 26% (31×) 23× – Possible
damaging
Damaging Disease causing
chr16:76495948 CNTNAP4 c.1210G>T, p.A404S Missense 33% (42×) 43× – Benign Tolerated Disease causing
chr17:10300120 MYH8 c.4362G>T, p.K1454N Missense 26% (38×) 33× – Deleterious – Disease causing
chr19:53057457 ZNF808 c.1288G>T, p.E430Ter Nonsense 43% (30×) 27× – – Tolerated Polymorphism
chr20:43385680 RIMS4 c.455-2T>A 3’ splice site 28% (29×) 37× – – – –
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The detection of copy number losses affecting ter-
minal segments of 11p and 22q suggested the presence
of the chromosomal translocation t(11;22)(p13;q12) in-
volving EWSR1 and WT1 genes.
Additionally, we used NGS data from the WES of the
tumor and patient’s leukocyte to search for CNAs, and
98.4% of the events detected by array CGH were validated,
demonstrating the efficacy of WES for identification of a
Fig. 1 Network analysis by IPA. a Interaction network of genes harboring protein-affecting somatic mutations (network score = 45) is
associated with the top disease and functions: cell death and survival, nervous system development and function, cellular compromise. b
Interaction network of genes harboring rare polymorphisms detected in homozygosis in the patient (network score = 12) is associated with
the top disease and functions: cell cycle, digestive system development and function, hair and skin development and function. c Interaction
network of genes affected by compound heterozygous variants (network score = 25) is associated with the top disease and functions: cancer,
organismal injury, abnormalities, and gastrointestinal disease. Continuous and dashed lines indicate direct and indirect interactions between
molecules, respectively. Blue molecules represent the genes encountered in our analysis and blank molecules represent other genes
automatically included by IPA. Molecules are displayed by various shapes depending on the functional class of the gene product, according
to IPA Path designer shapes (Additional file 7)
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wide range of somatic events, besides point mutations and
indels (Fig. 2b; Additional file 5: Table S3).
Establishment of a personalized monitoring strategy
based on detection of circulating tumor DNA (ctDNA)
The genomic translocation t(11;22)(p13;q12), which is
considered the molecular hallmark of this tumor type, was
initially detected by FISH analysis for diagnostic purposes.
Furthermore, the same translocation was also detected in
the array CGH and confirmed by whole-genome sequen-
cing. The mate-pair approach used for whole-genome
sequencing followed by validation by PCR and Sanger
sequencing allowed the precise delimitation of the
chromosomal breakpoints (Fig. 3). This somatic fusion
event was then used as a tumor biomarker for monitor-
ing the patient along the follow-up period using a liquid
biopsy-based approach. We searched for traces of cir-
culating tumor DNA in plasma samples collected 17,
36, 42, and 47 months after surgery. No signs of the
translocation in any of the post-treatment plasma sam-
ples were detected (Fig. 3) using digital droplet PCR
(ddPCR). The absence of the biomarker in any of the
post-treatment plasma samples is in agreement with
favorable clinical response of the patient, showing long-
term disease-free survival and no sign of disease recur-
rence. As a positive control, we confirmed the presence
of cell-free circulating DNA by detecting non-rearranged
WT1 gene in all plasma samples.
Despite the unavailability of plasma samples at the
moment of diagnosis and before treatment (neoadjuvant/
adjuvant chemotherapy and surgery) to be used as a base-
line positive control, we carried out stringent control
assays. We tested the robustness of the approach by evalu-
ating six different amounts of tumor DNA, ranging from
60 ng to 6 pg, and searched for both the tumor-specific
fusion event and for the non-rearranged WT1 gene. We
achieved a linear quantification of tumor marker and
wild-type DNA, and we were able to discriminate the
presence of the fusion event even in extremely low
quantity of DNA (6 pg) (Fig. 3d). To test the specificity
of the ddPCR assay, we used leukocyte sample of the
patient and also DNA from plasma and leukocyte sam-
ples of healthy donors, and the absence of detection of
tumor-specific fusion confirmed the assay specificity
for tumor DNA, without false positive signals (Additional
file 6: Figure S2). Further, we mimicked a situation of
circulating tumor DNA in body fluid by mixing 1 part of
tumor DNA to 100 and 1000 parts of leukocyte DNA,
then screened for the fusion event using 1 ng of this DNA
mix. Typically, the detection of circulating tumor DNA
has been reported as a fraction between 0.1 and 90% of
plasma DNA for cancer patients, depending on tumor
type and patient characteristics [27]. Here, we were able to
detect the fusion event in the 1.0 and 0.1% fractions,
supporting the reliability of our established approach
for patient surveillance based on liquid-biopsy screening.
Discussion
DSRCT is an aggressive tumor not yet broadly investi-
gated with the powerful genomic tools available. Mainly
due to the rarity of this disease, only a few studies inves-
tigated molecular alterations in this tumor type. Shukla
et al. [8] screened the occurrence of 275 COSMIC muta-
tions in 29 oncogenes and found no alterations in any of
the 24 DSRCT samples investigated. More recently, a study
based on targeted exome sequencing of six adult patients
with pediatric-type malignancies found AURKB and MCL1
amplifications and variants of unknown clinical significance
in ARID1A and RUNX1 genes in one DSRCT [6].
Here, by performing a comprehensive screening of the
genomic alterations in a family based approach, we identi-
fied somatic and germline variants possibly associated
with DSRCT. In our study, the use of a commercially
available gene panel did not show to be an adequate strat-
egy. Based on this finding, one can argue that screening
by commercially available gene panels is not an effective
approach for most cases of rare tumors, since the targeted
genes represented in these panels are usually those well
characterized in common solid tumors. On the other
hand, the use of WES not only revealed mutated genes
but also showed robustness for detecting DNA copy num-
ber alterations. Concordance rates between WES and



















VEZT c.1486G > A p.V496I Missense rs10507051 (0.0302) 100% / 17 17.9% / 28 35.0% / 80 PD T DC
ISX c.248G > A p.R83Q Missense rs8140287 (0.0308) 100% / 13 37.5% / 24 50.0% / 70 PrD T DC
RASSF1 c.409G > T p.A137S Missense rs2073498 (0.0711) 83.3% / 12 27.5% / 40 53.1% / 32 B T P
ADAMTS12 c.3529 T > C p.W1177R Missense rs3813474 (0.0513) 100% / 51 42.0% / 88 45.0% / 40 B T P
MAF Minor allele frequency, PrD Probably damaging, B Benign, PD Possibly damaging, D Damaging, T Tolerated, DC Disease causing, P Polymorphism. (*) low
confidence prediction
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array CGH (the gold standard for CNA screening) were
above 98% (Fig. 2). Among the CNAs not detected in the
WES analysis, two of them were mapped to regions not
covered by the library probes and five were low-level
mosaic alterations (Additional file 3: Table S2). Thus, if we
consider CNAs mapping to WES target regions and non-
mosaic CNAs, concordance rates were above 99.8%.
In total, 38 somatically acquired alterations, including
point mutations (15) and CNAs (23), were detected. The
small number of somatic alterations identified here is in
agreement with what is expected for pediatric tumors
[28]. Moreover, given the occurrence of the driver EWS-
WT1 fusion protein, additional oncogenic mutations for
tumor onset is probably less necessary.
Table 3 Description of compound heterozygous variants detected in the DSRCT patient. Each one of the variants was exclusively
inherited by one of the parents. The genotype and variant frequency were obtained by leukocyte DNA sequencing. All variants were












C2CD3 c.5653 T > C p.S1885P rs142277857
(0.001)
T/C 43.1 T/T - T/C 53.57 PrD D P
c.3223A > C p.S1075R - A/A - A/C 50.91 A/C 41.67 PrD D DC
FAM13C c.1361G > A p.R454H rs369226393 G/A 56.4 G/G - G/A 50 B T P
c.439C > T p.P147S rs73299227
(0.0092)
C/C - C/T 51,43 C/T 36.36 PD D* DC
GOLGA3 c.209G > A p.G70E rs2291256
(0.0581)
G/A 52.3 G/G - G/A 47.06 B D* P
c.3728G > A p.R1243Q rs140646528
(0.0134)
G/G - G/A 60 G/A 25 B T P
LAMB2 c.1424G > A p.R475Q rs370565848 G/A 36.4 G/G - G/A 60 PrD T P
c.5293G > A p.A1765T rs74951356
(0.0130)
G/G - G/A 55.81 G/A 41.18 B T DC
MTMR6 c.685C > G p.P229A rs149526134
(0.0002)
C/G 60.9 C/C - C/G 26.32 B T P
c.1795G > A p.A599T rs62619824
(0.0571
G/G - G/A 35.09 G/A 51.85 B T DC
RSPH1 c.742G > A p.G248R rs117385282
(0.0839)
G/A 50 G/G - G/A 31.25 B T P
c.733G > A p.G245R rs151158140
(0.0026)
G/G - G/A 50.77 G/A 58.33 PD T P
SLC9A9 c.1765A > G p.I589V rs2289491
(0.0290)
A/G 31.1 A/A - A/G 28 B T P
c.1618A > G p.I540V rs16853300
(0.0066)
A/A - A/G 48.62 A/G 36.36 B T P
SPICE1 c.2470A > C p.T824P rs57006145
(0.0313)
A/C 40.4 A/A - A/C 62.16 PrD T DC
c.850G > A p.V284M rs73239152
(0.0078)
G/G - G/A 47.54 G/A 29.27 B D DC
SYNE1 c.16277C > T p.T5426M rs2306914
(0.0463)





G/G - G/C 49.15 G/C 28.57 PrD D P
TAF5L c.721G > A p.V241I rs55655740
(0.0042)
G/A 36.0 G/G - G/A 48 B - DC
c.1123A > G p.T375A rs41304137
(0.0008)
A/A - A/G 20 A/G 40 PrD T P




T/C 40.0 T/T - T/C 57.69 - - P
c.65147C > T p.S21716L rs13021201
(0.0108)
C/C - C/T 42.86 C/T 58.14 - - P
MAF Minor allele frequency, PrD Probably damaging, B Benign, PD Possibly damaging, D Damaging, T Tolerated, DC Disease causing, P Polymorphism. (*) low
confidence prediction
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Fig. 2 (See legend on next page.)
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Fig. 3 Use of the chromosomal translocation t(11;22)(p13;q12) as a personalized tool for patient monitoring along follow-up. a FISH analysis shows
break apart probes for WT1 gene, indicating the occurrence of the fusion. b Mate-pair whole-genome sequencing detected paired reads mapping to
EWS and WT1 genes. c PCR amplification followed by Sanger sequencing confirmed the breakpoint region involving intronic regions of EWS and WT1
genes. d Digital droplet PCR assays for detection of the somatic rearrangement EWS-WT1. Left panel—Screening of ctDNA from plasma samples
collected serially along patient follow-up by ddPCR. No gene fusion was detected in ctDNA from the patient collected in four different time
points after surgery, suggesting no relapse, recurrence, or progression of the disease. Presence of cell-free DNA is shown by detection of
non-rearranged WT1 probes in the plasma samples from the patient and from control plasma sample. Middle panel—Serial dilutions of tumor
DNA to check the sensibility of the approach in detecting the fusion event, starting from 60 ng of input following five dilution series of
tenfold as indicated. Right panel—Detection of somatic rearrangement in different tumor DNA fractions, 1.0 and 0.1%
(See figure on previous page.)
Fig. 2 Array CGH profile showing the pattern of somatic copy number alterations detected in the DSRCT genome. a Copy number alterations detected
by array CGH analysis using a 180-K platform with an effective resolution of ~70 Kb: aneuploidy of chromosomes 5 and 18 (gains, in blue), and partial
losses of chromosome 13q, 11p, and 22q (in red). The green circle indicates the focal deletion of a segment of 1.3 Mb at 9p24.1. Arrows indicate
chromosome 11 and chromosome 22 breakpoints, 11p13 and 22q12.2, respectively. b Circus plot shows the copy number alterations detected by array
CGH and WES. Only the genomic regions affected by CNA events are represented. The numbers on each chromosome region are described in
megabases. In blue, data from array CGH and in green data from WES. A great overlap of CNA detection can be observed using both approaches
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We identified 12 genes affected by somatic mutations
possibly involved with the disease. These genes are in-
volved with cellular development and morphology that are
pathways in which WT1 gene plays an important role.
Similarly, the genes affected by compound heterozygous
mutations showed enrichment in biological processes of
muscle tissue development and morphogenesis. Altogether,
these data suggests that disruption of the embryonic cellu-
lar development process is involved with DSRCT onset,
which is commonly seen in pediatric tumors.
Another interesting finding is that among the set of
somatically mutated genes, 8 showed to be mutated in
desmoplastic melanoma samples from TCGA project
[29, 30], in frequencies ranging from 5 to 25% of the 20
samples interrogated. This data suggests that mutation
in these genes might be involved with the desmoplastic
phenotype, seen in both tumor types.
Additionally, 7 out of 15 genes harboring somatic mu-
tations (CHL1, MEGF10, MEIS2, MYH8, RIMS4, TBPL1,
and ZFPM2) are regulated by the same transcription fac-
tor, LEF1 (p < 0.001 by enrichment analysis), which, in
turn, is regulated by WT1 [31]. We therefore postulate
that DSRCT tumors presenting increased activity of WT1
due to EWS-WT1 fusion might upregulate the expression
of several genes mediated by LEF1 transcription factor.
However, the accumulation of mutations in this set of genes
regulated by LEF1 activation and its interrelation with the
EWS-WT1 fusion protein remains to be addressed.
Finally, the definition of the precise genomic breakpoint
of the t(11;22)(p13;q12) translocation by whole-genome
and Sanger sequencing enabled the development of a per-
sonalized tool to precisely monitor the presence of ctDNA
in plasma samples during the patient’s follow-up. Detec-
tion of tumor-specific genomic rearrangements has been
shown as a sensitive and specific method for monitoring
of disease status of cancer patients [32–35] and has clear
advantages over point mutations concerning the specifi-
city of detection [33]. Here, we applied ctDNA screening
in plasma samples collected in three clinical appointments
during 3 years after surgery and, up to now, we did not
detect the presence of this tumor marker. These results
are in agreement with imaging exams (CT scan and
PET scan) showing no signs of disease and also with
good overall clinical condition of the patient and high-
light the applicability of using genomic rearrangement
for building personalized tool for patient surveillance.
After defining the genomic breakpoint of EWS-WT1
fusion, DSRCT patients can benefit from a highly spe-
cific test that has the advantage of a rapid turnaround
time and potentially higher sensitivity in detecting dis-
ease progression earlier than imaging exams or other
cancer antigens measurements, as reported for other
tumor types [36, 37]. Monitoring through liquid biopsy
is particularly attractive for solid tumors, which cannot
be repeatedly sampled without more invasive proce-
dures. Considering the rarity of this subtype of sarcoma
and the lack of effective treatment, the detection of spe-
cific tumor marker and the monitoring of its persistence
can improve the identification of patients with worse
prognosis to tailor the treatment more properly. Thus,
the perspective is to employ the approach used here for
new patients and improve the outcome for those with
worse prognosis.
Conclusion
To our knowledge, this is the first comprehensive gen-
omic characterization of one DSRCT case. Continuous
efforts to establish the genomic landscape of rare dis-
eases, frequently neglected in large sequencing consor-
tiums, are highly significant to improve the knowledge
of defective pathways involved with tumor onset in
general, in addition to the strong potential of revealing
druggable targets for clinical use.
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